Skip to main content
Skip to main navigation
Invalid credentials.
Search for :
Product Development Strategy
Early Clinical Development
Phase I/IIa Clinical Trials
Phase II/III Clinical Trials
Interventional Phase IIIb/Phase IV Clinical Trials
Observational Research & Registries
Product Launch & Management
Market Access Solutions
Strategic Sales Outsourcing
Biopharmaceutical R&D
Biopharmaceutical Sales & Marketing
Biosimilars
Healthcare Payers & Providers
Medical Device & Diagnostics
Public Health & Government
Cardiovascular
Central Nervous System
Diabetes & Endocrinology
Infectious Diseases
Internal Medicine
Oncology
Early Phase Oncology
Translational Oncology
Pediatrics
Public Health Interest
Vaccines
Other Therapeutic Areas
Our Focus
Our Values
Our Heritage
Our Perspectives
Our Leadership
Ethics & Compliance
Investors
My Library
Quintiles Files Registration Statement for Initial Public Offering
Quintiles Unlocks Path for Digital Patient Engagement
The Data Driven Difference
The Future Healthcare Ecosystem
The Data Driven Difference – Planning & Design
Strategic Planning and Design
Quintiles Infosario™
Expression Analysis Announces 2013 Grant Program
Quintiles Rated Industry Leader and Highest in Service Quality in Phase II/III Clinical Research
A Comprehensive Range of Services for Insourcing
Is Your Deviation Investigation System Effective and Compliant?
Real-World and Late Phase Oncology Expertise: Stronger Evidence, Healthier Results
Merck Serono and Quintiles Announce Innovative Clinical Development Partnership
Quintiles Announces Completion of Initial Public Offering of 27,236,841 Shares of Common Stock
Risk-based Approach to Monitoring: Deployment Insights and Lessons Learned
Risk-based Approach to Monitoring: The Future Roles of People, Process & Technology